查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790472

美國質體DNA 製造市場規模、佔有率和趨勢分析報告：按疾病、等級、應用、開發階段和細分市場預測，2025 年至 2033 年

U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國質體DNA製造市場摘要

美國質體DNA 製造市場預計在 2024 年價值 8.03 億美元，預計到 2033 年將達到 50.38 億美元，2025 年至 2033 年的複合年成長率為 23.06%。這一擴張是由對基因療法、DNA 疫苗和其他使用高品質質體DNA 作為其組成部分的先進生技藥品的需求不斷成長所推動的。

預計在預測期內，對生物技術研究的持續投資和支持性法律規範將進一步推動市場發展。

遺傳疾病和癌症盛行率上升

遺傳疾病和癌症的發生率不斷上升是推動美國質體DNA製造業成長的主要因素。基因研究的進展揭示了基因突變和異常在各種疾病中的作用，從而促進了旨在從根本上治癒這些疾病的基因療法的發展。同樣，癌症治療也正朝著個人化和標靶治療的方向發展，其中許多療法都依賴質體DNA作為載體來遞送治療基因或免疫調節劑。隨著診斷技術的進步和人口老化，越來越多的患者被確定為這些創新治療方法的候選人，從而擴大了對質體DNA的需求。

此外，基因療法和癌症治療的複雜性和個人化特性要求質體DNA的生產過程高度專業化且可擴展。生物技術公司和研究機構正在大力投資開發靈活的生產平台，以滿足臨床和商業應用的嚴格品質標準和數量要求。精準醫療和個人化治療日益受到關注，推動著市場持續擴張，而質體DNA在先進療法的研發中發揮關鍵作用。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢與展望
  • 市場動態
    • 選擇基因治療的患者數量不斷增加
    • 強大的基因治療管道
    • 市場競爭激烈，市場參與企業策略多元
    • 各種醫療治療對質體DNA 的需求不斷增加
  • 市場限制因素分析
    • 與基因治療相關的監管、科學和倫理挑戰
  • 商業環境分析
    • PESTEL分析
    • 波特五力分析

第4章 等級商業分析

  • 細分儀表板
  • 美國質體DNA製造市場的波動
  • 美國質體DNA 製造市場規模及趨勢分析（依等級）（2021-2033）
  • 研發級
    • 研發級市場，2021-2033
    • 病毒載體開發
    • mRNA發育
    • 抗體開發
    • DNA疫苗開發
    • 其他
  • GMP級
    • GMP級市場，2021-2033年

第5章：開發階段的商業分析

  • 細分儀表板
  • 美國質體DNA製造市場的波動
  • 美國質體DNA 製造市場規模及發展階段趨勢分析（2021-2033 年）
  • 臨床前治療
  • 臨床治療
  • 非處方藥

第6章：應用業務分析

  • 細分儀表板
  • 美國質體DNA製造市場的波動
  • 美國質體DNA 製造市場規模與趨勢分析（按應用）（2021-2033）
  • DNA疫苗
  • 細胞和基因治療
  • 免疫療法
  • 其他

第7章疾病業務分析

  • 細分儀表板
  • 美國質體DNA製造市場的波動
  • 美國質體DNA 製造市場規模與趨勢分析（按疾病，2021-2033 年）
  • 感染疾病
  • 癌症
  • 遺傳性疾病
  • 其他

第8章 競爭態勢

  • 參與企業
  • 2024年企業市場分析
  • 參與企業概況
    • Charles River Laboratories
    • Danaher（Aldevron）
    • VGXI, Inc.
    • Kaneka Corp.
    • Lonza
    • Nature Technology
    • Cell and Gene Therapy Catapult
    • Eurofins Genomics
    • Luminous BioSciences, LLC
    • Akron Biotech
Product Code: GVR-4-68040-287-0

U.S. Plasmid DNA Manufacturing Market Summary

The U.S. plasmid DNA manufacturing market size was estimated at USD 803.0 million in 2024 and is projected to reach USD 5,038.0 million by 2033, growing at a CAGR of 23.06% from 2025 to 2033. This expansion is driven by increasing demand for gene therapies, DNA vaccines, and other advanced biologics that rely on high-quality plasmid DNA as a foundational component.

Continued investment in biotechnology research and supportive regulatory frameworks are expected to propel market development further over the forecast period.

Rising Prevalence of Genetic Disorders and Cancer

The rising prevalence of genetic disorders and cancer is a major factor driving growth in the U.S. plasmid DNA manufacturing industry. Advances in genetic research have highlighted the role of gene mutations and abnormalities in various diseases, leading to increased development of gene therapies aimed at treating these conditions at their source. Similarly, cancer treatment is increasingly shifting toward personalized and targeted therapies, many of which depend on plasmid DNA as a vector to deliver therapeutic genes or immune modulators. As diagnostic technologies improve and the population ages, more patients are identified as candidates for these innovative therapies, expanding the demand for plasmid DNA.

Moreover, the complex and individualized nature of genetic and cancer therapies requires highly specialized and scalable plasmid DNA manufacturing processes. Biotech companies and research institutions invest heavily in developing flexible production platforms that meet the' rigorous quality standards and volume demands of clinical and commercial applications. This increased focus on precision medicine and tailored treatments further solidifies plasmid DNA's role as a critical component in the evolving landscape of advanced therapeutics, driving sustained market expansion.

U.S. Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. plasmid DNA manufacturing market report based on grade, development phase, application, and disease:

  • Grade Outlook (Revenue, USD Million, 2021 - 2033)
  • R&D Grade
    • Viral Vector Development
    • AAV
    • Lentivirus
    • Adenovirus
    • Retrovirus
    • Others
    • mRNA Development
    • Antibody Development
    • DNA Vaccine Development
    • Others
  • GMP Grade
  • Development Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-Clinical Therapeutics
  • Clinical Therapeutics
  • Marketed Therapeutics
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • DNA Vaccines
  • Cell & Gene Therapy
  • Immunotherapy
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Disease
  • Cancer
  • Genetic Disorder
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Grade
    • 1.2.2. Development Phase
    • 1.2.3. Application
    • 1.2.4. Disease
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
    • 1.9.1. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increasing number of patients opting for gene therapy
    • 3.3.2. Robust pipeline for gene therapies
    • 3.3.3. Highly competitive market and various strategies undertaken by market players
    • 3.3.4. Increasing demand for plasmid DNA in various medical therapies
  • 3.4. Market Restraint Analysis
    • 3.4.1. Regulatory, scientific, and ethical challenges associated with gene therapy
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Grade Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
  • 4.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
  • 4.4. R&D Grade
    • 4.4.1. R&D Grade Market, 2021 - 2033 (USD Million)
    • 4.4.2. Viral Vector Development
      • 4.4.2.1. Viral Vector Development Market, 2021 - 2033 (USD Million)
      • 4.4.2.2. AAV
        • 4.4.2.2.1. AAV Market, 2021 - 2033 (USD Million)
      • 4.4.2.3. Lentivirus
        • 4.4.2.3.1. Lentivirus Market, 2021 - 2033 (USD Million)
      • 4.4.2.4. Adenovirus
        • 4.4.2.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
      • 4.4.2.5. Retrovirus
        • 4.4.2.5.1. Retrovirus Market, 2021 - 2033 (USD Million)
      • 4.4.2.6. Others
        • 4.4.2.6.1. Others Market, 2021 - 2033 (USD Million)
    • 4.4.3. mRNA Development
      • 4.4.3.1. mRNA Development Market, 2021 - 2033 (USD Million)
    • 4.4.4. Antibody Development
      • 4.4.4.1. Antibody Development Market, 2021 - 2033 (USD Million)
    • 4.4.5. DNA Vaccine Development
      • 4.4.5.1. DNA Vaccine Development Market, 2021 - 2033 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5. GMP Grade
    • 4.5.1. GMP Grade Market, 2021 - 2033 (USD Million)

Chapter 5. Development Phase Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
  • 5.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
  • 5.4. Pre-Clinical Therapeutics
    • 5.4.1. Pre-Clinical Therapeutics Market, 2021 - 2033 (USD Million)
  • 5.5. Clinical Therapeutics
    • 5.5.1. Clinical Therapeutics Market, 2021 - 2033 (USD Million)
  • 5.6. Marketed Therapeutics
    • 5.6.1. Marketed Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
  • 6.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. DNA Vaccines
    • 6.4.1. DNA Vaccines Market, 2021 - 2033 (USD Million)
  • 6.5. Cell & Gene Therapy
    • 6.5.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
  • 6.6. Immunotherapy
    • 6.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Disease Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
  • 7.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 7.4. Infectious Disease
    • 7.4.1. Infectious Disease Market, 2021 - 2033 (USD Million)
  • 7.5. Cancer
    • 7.5.1. Cancer Market, 2021 - 2033 (USD Million)
  • 7.6. Genetic Disorder
    • 7.6.1. Genetic Disorder Market, 2021 - 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Participant's Overview
    • 8.3.1. Charles River Laboratories
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Danaher (Aldevron)
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. VGXI, Inc.
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Kaneka Corp.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Lonza
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Nature Technology
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Cell and Gene Therapy Catapult
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Eurofins Genomics
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Luminous BioSciences, LLC
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Akron Biotech
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 U.S. Plasmid DNA Manufacturing Market by Grade, 2021 - 2033 (USD Million)
  • Table 4 U.S. Plasmid DNA Manufacturing Market by Development Phase, 2021 - 2033 (USD Million)
  • Table 5 U.S. Plasmid DNA Manufacturing Market by Application, 2021 - 2033 (USD Million)
  • Table 6 U.S. Plasmid DNA Manufacturing Market by Disease, 2021 - 2033 (USD Million)
  • Table 7 Participant's Overview

List of Figures

  • Fig. 1 U.S. plasmid DNA manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 U.S. plasmid DNA manufacturing market driver analysis
  • Fig. 12 U.S. plasmid DNA manufacturing market restraint analysis
  • Fig. 13 U.S. plasmid DNA manufacturing market: Porter's analysis
  • Fig. 14 U.S. plasmid DNA manufacturing market: PESTEL analysis
  • Fig. 15 U.S. plasmid DNA manufacturing market: Grade outlook and key takeaways
  • Fig. 16 U.S. plasmid DNA manufacturing market: Grade movement analysis
  • Fig. 17 U.S. R&D grade market, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. viral vector development market, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. mRNA development market, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. antibody development market, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. DNA vaccine development market, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. others market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. AAV market, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. lentivirus market, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. adenovirus market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. retrovirus market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. GMP grade market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. others market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. plasmid DNA manufacturing market: Development phase outlook and key takeaways
  • Fig. 30 U.S. plasmid DNA manufacturing market: Development phase movement analysis
  • Fig. 31 U.S. pre-clinical therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. clinical therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. marketed therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. plasmid DNA manufacturing market: Application outlook and key takeaways
  • Fig. 35 U.S. plasmid DNA manufacturing market: Application movement analysis
  • Fig. 36 U.S. DNA vaccines market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. cell & gene therapy market, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. others market, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. plasmid DNA manufacturing market: Disease outlook and key takeaways
  • Fig. 41 U.S. plasmid DNA manufacturing market: Disease movement analysis
  • Fig. 42 U.S. infectious disease market, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. cancer market, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. genetic disorder market, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. others market, 2021 - 2033 (USD Million)